- Home
- MGIC vs CGEN Comparison
MGIC vs CGEN Comparison
Compare MGIC & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGIC
- CGEN
- Stock Information
- Founded
- MGIC 1983
- CGEN 1993
- Country
- MGIC Israel
- CGEN Israel
- Employees
- MGIC N/A
- CGEN N/A
- Industry
- MGIC Computer Software: Prepackaged Software
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MGIC Technology
- CGEN Health Care
- Exchange
- MGIC Nasdaq
- CGEN Nasdaq
- Market Cap
- MGIC N/A
- CGEN 134.3M
- IPO Year
- MGIC 1991
- CGEN 2000
- Fundamental
- Price
- MGIC $11.89
- CGEN $1.65
- Analyst Decision
- MGIC Buy
- CGEN Strong Buy
- Analyst Count
- MGIC 1
- CGEN 1
- Target Price
- MGIC $15.00
- CGEN $4.00
- AVG Volume (30 Days)
- MGIC 42.2K
- CGEN 470.1K
- Earning Date
- MGIC 11-18-2024
- CGEN 11-12-2024
- Dividend Yield
- MGIC 1.71%
- CGEN N/A
- EPS Growth
- MGIC N/A
- CGEN N/A
- EPS
- MGIC 0.70
- CGEN 0.02
- Revenue
- MGIC $535,482,999.00
- CGEN $59,852,000.00
- Revenue This Year
- MGIC $4.29
- CGEN $57.27
- Revenue Next Year
- MGIC $3.39
- CGEN N/A
- P/E Ratio
- MGIC $17.20
- CGEN $85.40
- Revenue Growth
- MGIC N/A
- CGEN 698.03
- 52 Week Low
- MGIC $9.38
- CGEN $1.35
- 52 Week High
- MGIC $13.40
- CGEN $3.03
- Technical
- Relative Strength Index (RSI)
- MGIC 49.67
- CGEN 56.57
- Support Level
- MGIC $11.51
- CGEN $1.47
- Resistance Level
- MGIC $12.24
- CGEN $1.65
- Average True Range (ATR)
- MGIC 0.30
- CGEN 0.10
- MACD
- MGIC -0.07
- CGEN 0.00
- Stochastic Oscillator
- MGIC 33.33
- CGEN 80.80
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.